BioSpace News Archive

Sartorius Stedim Biotech S.A. will postpone its Annual General Shareholders’ Meeting formerly scheduled for March 24, 2020, to a later date due to the coronavirus pandemic and the associated restrictions imposed on travel and meetings.

Earlier this year, the lab of Xavier Saelens (VIB-UGent) announced the discovery of a unique antibody that is capable of binding the virus that causes COVID-19 (SARS-CoV-2). The antibody was developed in collaboration with two research groups in the US.

Since December 2019, the world is facing the new coronavirus challenge, and measures have been taken against the outbreak. The continuously increasing number of prevalence of coronavirus infected patients and the death cases clearly show, that there is no therapy against coronaviruses yet.

As the coronavirus continues to spread and impact Americans throughout the country, lawmakers are cutting red tape and clearing the way for frontline providers, such as pharmacists, to be a greater resource to patients during these troubling times.

NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of ambulatory-focused technology solutions, today announced that NextGen® Patient Experience Platform is now available.

Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, provided a business update for the fourth quarter and full year 2019.

Pulse Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 102,500 shares of Pulse Biosciences common stock to recently hired non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on March 16, 2020.

SmileDirectClub, the industry pioneer and first direct-to-consumer medtech platform for teeth straightening, reports that the American Association of Dental Boards has issued the first Telehealth Directive to its member dental boards touting the necessity for accessible care through teledentistry.

Todos Medical Ltd. (TOMDF), a pre-commercial stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it has entered into a non-exclusive distribution agreement with 3D Biomedicine Science & Technology Co.,

Todos Medical Ltd. (OTCQB: TOMDF), a pre-commercial stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it has entered into a non-exclusive distribution agreement with 3DMedicine Science & Technology Co (3DMed)